Clinical Trials Logo

Cognition Disorders clinical trials

View clinical trials related to Cognition Disorders.

Filter by:

NCT ID: NCT02740634 Recruiting - Alzheimer Disease Clinical Trials

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Start date: May 2016
Phase: N/A
Study type: Interventional

This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.

NCT ID: NCT02736396 Completed - Cognition Disorders Clinical Trials

Southend Imaging Study

SIS
Start date: June 2016
Phase:
Study type: Observational

The study objective is to correlate global cognition and episodic memory performance to resting state fMRI functional connectivity. This is a non-treatment, prospective, natural history data collection study in a cross-sectional cohort of patients with cognitive impairment.

NCT ID: NCT02719470 Completed - Parkinson's Disease Clinical Trials

Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?

Start date: January 2014
Phase: N/A
Study type: Interventional

In order to explore the question how an intensive, goal-based and aerobic rehabilitation treatment, addressed to act on motor and mental aspects, affects motor and functional symptoms in PD patients with normal cognition and with different level of cognitive impairment. Hypothesis is that a specific rehabilitation program based on motor-cognitive training and repetition, can affect positively the rehabilitation outcome regardless of baseline cognitive profile.

NCT ID: NCT02706210 Recruiting - Clinical trials for Mild Cognitive Impairment

Magnetic Resonance Imaging-based Comparative Research in Different Mild Cognitive Impairment Subtype

Start date: September 2015
Phase: N/A
Study type: Observational

Dementia is one of the main chronic non-communicable diseases associated with disability, institutionalization, and mortality among elderly individuals. Alzheimer's disease (AD) and vascular dementia (VD) are considered to be the main types of dementia. A widely shared view is that future treatment strategies need to focus on treatment of the earliest stages of the disease. Mild cognitive impairment (MCI) constitutes an intermediate stage between normal aging and dementia. Vascular cognitive disorders (VCD) is an umbrella term representing a wide spectrum of cognitive disorder evoked by or associated with vascular causes. It encompasses patients suffering from a range of types of cognitive impairment, from mild impairment to VD. VCD predementia (VCD-P) is at the same stage of MCI. Amnestic MCI (aMCI) is a subtype of MCI, which is also considered to be the clinical transition stage between normal aging and AD, and has been applied to detect the emerging dementia. In VCD, infarcts or profuse white matter disease are considered the cause of cognitive decline. By contrast, AD is one of the most common progressive neurodegenerative disorders thought to be caused by amyloid aggregation and the formation of tau tangles. Both VCD-P and aMCI have a deficit in cognitive domains, and may have the same chief complaints of memory deficit. If it can be clear which will turn into what type of dementia in patients with cognitive impairment stage, it can not only make us more early intervention treatment to the patients, but also can save a lot of social resources and economic costs in clinic. By applying the resting state functional magnetic resonance (fMRI), structural magnetic resonance imaging (sMRI) and diffusion tensor magnetic resonance imaging (DTI) multimodal magnetic resonance (NMR) technology, the project comprehensive analysis comparison of neurodegenerative and blood vessels of brain function in patients with mild cognitive impairment and structural abnormalities connection mode. This project in order to reveal the cognitive impairment disease neural circuits in the development of the network connection and its change rule. People can further understand the pathogenesis of cognitive impairment, discover new will provide a scientific basis for prevention, diagnosis and treatment.

NCT ID: NCT02702817 Completed - Alzheimer Disease Clinical Trials

Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia

Start date: August 1, 2012
Phase: Phase 2
Study type: Interventional

Two-year double-masked trial of over-the-counter dosage of naproxen sodium vs placebo in 200 cognitively normal participants with a parental or multiplex first-degree family history Alzheimer's disease (AD) dementia. Primary outcomes are decline in cognitive function and slope of change in a summary Alzheimer Progression Score derived from serial assessment of neuroimaging, biochemical, and sensori-neural biomarker indicators of pre-clinical disease -- all believed likely to reflect progress of preclinical AD in this high risk cohort. Approximately 2/3 of participants have volunteered also for serial lumbar punctures for analysis of cerebrospinal fluid. A two-year off-treatment delayed-washout phase is planned to examine sustained treatment effects and evidence of disease modification.

NCT ID: NCT02701855 Recruiting - Hypertension Clinical Trials

Retina Microvascular Remodeling and Cognitive Function In Hypertension

EYEBRAIN
Start date: October 2014
Phase: N/A
Study type: Observational

This study aims to determine the relationships between retina micro-vascular remodeling and cognitive function in hypertensive patients. The study plans to enrol 160 patients (100 patients with mild cognitive impairment -MCI- and 60 without MCI).

NCT ID: NCT02699476 Recruiting - Clinical trials for Traumatic Brain Injury

Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.

Start date: February 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to compare different combinations of cognitive training in retired professional football players and military veterans with a history of repeated concussions and persistent symptoms of impaired memory, concentration, attention, focus, or thinking.

NCT ID: NCT02681354 Completed - Clinical trials for Mild Cognitive Impairment

Dual Task Training in Elderly Using the BioRescue

Start date: November 2015
Phase: N/A
Study type: Interventional

Mild cognitive impairment (MCI) is accompanied by gait and balance problems while dual tasking. During a 6 to 8 weeks training with the BioRescue (virtual reality), institutionalized elderly people with MCI will relearn dual tasks in combination with balance. Afterwards, the transferring effect on gait in general, balance and cognition will be examined.

NCT ID: NCT02680210 Completed - Cognition Disorders Clinical Trials

Self-defining Memories in Patients With a TBI

IDENTITY
Start date: February 4, 2016
Phase: N/A
Study type: Interventional

The study will be conducted over 18 months. The main objective of this study is to explore the relationships between autobiographical memory and specific cognitive measures, as well as emotional and behavioural measures in patients who have suffered a moderate to severe TBI. Secondary objectives are to assess the psychometric properties of a self-defining memories questionnaire and to characterize autobiographical memory in the TBI population.

NCT ID: NCT02671526 Completed - Clinical trials for HIV-associated Neurocognitive Dysfunction

Cognitive Remediation for HIV-associated Neurocognitive Dysfunction

HAND
Start date: December 2015
Phase: N/A
Study type: Interventional

This study is a validation study to document the acceptability of the revised Plasticity-based Adaptive Cognitive Remediation (PACR) program to patients with HIV-associated Neurocognitive Dysfunction (HAND). The primary objective of this study is to evaluate the effects of the revised PACR program on the cognitive abilities (e.g., attention, executive function), functional status and quality of life of individuals diagnosed with HAND. The secondary objective of the study is to collect relevant data to support a pre-investigational device exemption (IDE) submission to the FDA required before the pivotal randomized, controlled trial planned for Phase II.